Abstract
The rising number of elderly people has a major impact on healthcare systems. Advancing age is a risk factor for the development of cardiovascular disease (CVD), which represents a major global healthcare problem. The clinical efficacy and safety of lipid lowering treatment (especially statins) is well established following a series of large-scale, randomised controlled trials, which mainly recruited patients under the age of 70 years. Subgroup analyses together with the findings of trials involving sufficient numbers of elderly participants, such as the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) and the Heart Protection Study (HPS) offer a basis for considering statin therapy in this population. Furthermore, since this population is at greater absolute risk of CVD, substantial benefits from adequate treatment may be anticipated. However, underevaluation and undertreatment appear to be common in the elderly. In this review, we provide a survey of potentially modifiable cardiovascular risk factors in association with old age, and discuss the relevant findings of large-scale end-point clinical studies as well as major considerations regarding lipidlowering treatment in this population. It is concluded that the decision whether to treat hypercholesterolaemia in the elderly is currently individualised, depending upon the degree of risk, general health, willingness to receive treatment and financial concerns. Further, prospective randomised trials are required to guide physicians towards an effective management of older individuals at increased atherosclerotic risk.
Keywords: Cardiovascular disease, cholesterol lowering, elderly, lipids, prevention, statins
Current Pharmaceutical Design
Title: Lipid Lowering Therapy in the Elderly: Is there a Benefit?
Volume: 12 Issue: 30
Author(s): Kallirroi J. Kalantzi, Haralampos J. Milionis, Dimitri P. Mikhailidis and John A. Goudevenos
Affiliation:
Keywords: Cardiovascular disease, cholesterol lowering, elderly, lipids, prevention, statins
Abstract: The rising number of elderly people has a major impact on healthcare systems. Advancing age is a risk factor for the development of cardiovascular disease (CVD), which represents a major global healthcare problem. The clinical efficacy and safety of lipid lowering treatment (especially statins) is well established following a series of large-scale, randomised controlled trials, which mainly recruited patients under the age of 70 years. Subgroup analyses together with the findings of trials involving sufficient numbers of elderly participants, such as the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) and the Heart Protection Study (HPS) offer a basis for considering statin therapy in this population. Furthermore, since this population is at greater absolute risk of CVD, substantial benefits from adequate treatment may be anticipated. However, underevaluation and undertreatment appear to be common in the elderly. In this review, we provide a survey of potentially modifiable cardiovascular risk factors in association with old age, and discuss the relevant findings of large-scale end-point clinical studies as well as major considerations regarding lipidlowering treatment in this population. It is concluded that the decision whether to treat hypercholesterolaemia in the elderly is currently individualised, depending upon the degree of risk, general health, willingness to receive treatment and financial concerns. Further, prospective randomised trials are required to guide physicians towards an effective management of older individuals at increased atherosclerotic risk.
Export Options
About this article
Cite this article as:
Kalantzi Kallirroi J., Milionis Haralampos J., Mikhailidis Dimitri P. and Goudevenos John A., Lipid Lowering Therapy in the Elderly: Is there a Benefit?, Current Pharmaceutical Design 2006; 12 (30) . https://dx.doi.org/10.2174/138161206778559669
DOI https://dx.doi.org/10.2174/138161206778559669 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Efficacy and Cardiovascular Safety of Meglitinides
Current Drug Safety Folate Nutrigenetics: A Convergence of Dietary Folate Metabolism, Folic Acid Supplementation, and Folate Antagonist Pharmacogenetics
Drug Metabolism Letters A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Apolipoprotein(a) Antisense Oligonucleotides: A New Treatment Option for Lowering Elevated Lipoprotein(a)?
Current Pharmaceutical Design The Effect of Statins on Postprandial Lipemia
Current Drug Targets Statin Therapy for Native and Peri-Interventional Coronary Heart Disease
Current Molecular Medicine A Journey into the World of Targeted Therapy: A Review of Gene Therapy, Stem Cell Therapy, and Cell Reprogramming in Cardiovascular Medicine
Recent Patents on Regenerative Medicine Getting Patients to Target- Implementing the Guidelines
Current Vascular Pharmacology Effects and Perspectives of Chinese Patent Medicines for Tonifying <i>Qi</i> and Promoting Blood Circulation on Patients with Cerebral Infarction
Current Vascular Pharmacology Development and Characterization of Spray Dried Microparticles for Pulmonary Delivery of Antifungal Drug
Current Drug Delivery Malondialdehyde and Superoxide Dismutase in High-dose Calcium Supplemented Women in Relation to Iron and Calcium Panels
Current Nutrition & Food Science Drug Metabolizing Enzymes and Transporters mRNA in Peripheral Blood Mononuclear Cells of Healthy Subjects: Biological Variations and Importance of Preanalytical Steps
Current Drug Metabolism Having a Promising Efficacy on Type II Diabetes, It’s Definitely a Green Tea Time
Current Medicinal Chemistry Stem Cell Implantation for Myocardial Disorders
Current Drug Delivery Epidemiological and Maternal Features of Maternal Mortality in the West of Iran: Hamadan, 2011-2019
Current Women`s Health Reviews Tenofovir-Related Nephropathies in HIV-Infected Patients
Current Vascular Pharmacology Herb-Drug Interactions and Mechanistic and Clinical Considerations
Current Drug Metabolism MDMA Toxicity and Pathological Consequences: A Review About Experimental Data and Autopsy Findings
Current Pharmaceutical Biotechnology Nutriproteomics and Nutrigenomics: Exploring the Mechanism Behind omega-3 Polyunsaturated Fatty Acids, Homocysteine and Glucose Metabolism
Current Proteomics Urotensin-II Receptor Antagonists
Current Medicinal Chemistry